Program
palbociclib
Also written as “Palbociclib”, “PD-0332991” and “Palbociclib 125mg”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Sarcoma, Ewing · Squamous Cell Carcinoma of Head and Neck · COVID-19, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 291 open or running | phase 4since Jan 22, 2016 | Aug 30, 2005 | Dec 31, 2029phase 2 · NCT05226871 |
| biotx.ai | 10 open or running | phase 2since Apr 26, 2022 | Apr 26, 2022 | none ahead |
| Criterium | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| CSPC Pharmaceutical Group | 11 open or running | phase 1since Apr 16, 2025 | Apr 16, 2025 | Oct 2027phase 1 · NCT06941142 |
| iOMEDICO | 10 open or running | phase 2since Aug 25, 2016 | Aug 25, 2016 | none ahead |
| Megalabs | 10 open or running | phase 4since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| Merck | 11 open or running | phase 2since Jul 18, 2022 | Jul 18, 2022 | Dec 22, 2026phase 2 · NCT05468697 |
Also a collaborator on its studies: AstraZeneca and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Aug 30, 2005.
- Jan 6, 2015Phase 1 study in Hepatic InsufficiencyPfizer · NCT02334800 · 28 enrolled · United States
- Jul 13, 20152 phase 1 studiesPfizer · NCT02499146, NCT02501902
- Jul 13, 2015Phase 2 study in Squamous Cell Carcinoma of Head and NeckPfizer · NCT02499120 · 125 enrolled · United States, Czechia, Hungary and more
- Nov 6, 2015Phase 3 study in Breast NeoplasmsPfizer · NCT02600923 · 131 enrolled · Argentina, Brazil, Colombia and more
- Jan 22, 2016Phase 4 study in Breast NeoplasmsPfizer · NCT02679755 · 252 enrolled · Australia, India
- Aug 25, 2016iOMEDICO's first study: phase 2 study in Breast NeoplasmsNew to iOMEDICOiOMEDICO · NCT02894398 · 388 enrolled · Germany
- Jun 16, 2017Phase 1 study in Healthy VolunteerPfizer · NCT03220191 · 12 enrolled · United States
- Oct 9, 2018Phase 2 study in Sarcoma, EwingPfizer · NCT03709680 · 128 enrolled · United States, Brazil, Canada and more
- Sep 3, 2020Criterium's first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04567420 · 70 enrolled · United States
- Jan 26, 2022Phase 2 study in Breast NeoplasmsPfizer · NCT05226871 · 35 enrolled · United States, China, Mexico and more
- Apr 26, 2022biotx.ai's first study: phase 2 study in COVID-19New to biotx.aibiotx.ai · NCT05371275 · Germany
- Jul 18, 2022Merck's first study: phase 2 study in Carcinoma, Renal CellNew to MerckMerck · NCT05468697 · 60 enrolled · United States, Australia, Israel
- Mar 19, 2024Megalabs's first study: phase 4 study in BioequivalenceNew to MegalabsMegalabs · NCT06331715 · 24 enrolled · India
- Apr 16, 2025CSPC Pharmaceutical Group's first study: phase 1 study in Advanced Breast CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06941142 · 382 planned
Ahead
- Dec 22, 2026Primary completion: phase 2 study in Carcinoma, Renal CellMerck · NCT05468697
- Oct 2027Primary completion: phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142
- Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT04567420
- Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05226871
TargetBeta
“CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor”ChEMBL 37, by rule
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06941142Advanced Breast Cancer | 1 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 2027 | 382 |
| NCT06331715Bioequivalence · India | 4 | Completed | Megalabs | Apr 1, 2024 | 24 |
| NCT05468697Carcinoma, Renal Cell · United States, Australia, Israel | 2 | Active, not recruiting | Merck | Dec 22, 2026 | 60 |
| NCT05371275COVID-19 · Germany | 2 | Withdrawn | biotx.ai | Oct 2022 | 0 |
| NCT05226871Breast Neoplasms · United States, China, Mexico and more | 2 | Active, not recruiting | Pfizer | Dec 31, 2029 | 35 |
| NCT04567420Breast Neoplasms · United States | 2 | Active, not recruiting | Criterium | Dec 31, 2027 | 70 |
| NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more | 2 | Completed | Pfizer | Aug 26, 2024 | 128 |
| NCT03220191Healthy Volunteer · United States | 1 | Completed | Pfizer | Sep 3, 2017 | 12 |
| NCT02894398Breast Neoplasms · Germany | 2 | Completed | iOMEDICO | Feb 15, 2023 | 388 |
| NCT02679755Breast Neoplasms · Australia, India | 4 | Completed | Pfizer | Jul 25, 2019 | 252 |
| NCT02600923Breast Neoplasms · Argentina, Brazil, Colombia and more | 3 | Completed | Pfizer | May 28, 2019 | 131 |
| NCT02501902Metastatic Pancreatic Ductal Adenocarcinoma · United States, Spain | 1 | Completed | Pfizer | Oct 10, 2018 | 76 |
| NCT02499146Advanced Breast Cancer · China | 1 | Completed | Pfizer | Jul 31, 2018 | 26 |
| NCT02499120Squamous Cell Carcinoma of Head and Neck · United States, Czechia, Hungary and more | 2 | Completed | Pfizer | Jul 19, 2018 | 125 |
| NCT02334800Hepatic Insufficiency · United States | 1 | Completed | Pfizer | Oct 9, 2016 | 28 |
| NCT02311946Healthy · United States | 1 | Completed | Pfizer | Apr 2015 | 60 |
| NCT02297438Breast Neoplasms · China, Hong Kong, Singapore and more | 3 | Completed | Pfizer | Aug 31, 2020 | 340 |
| NCT02222441Healthy · United States | 1 | Completed | Pfizer | Dec 2014 | 14 |
| NCT02131298Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 12 |
| NCT02085538Renal Insufficiency · United States | 1 | Completed | Pfizer | May 2016 | 31 |
| NCT02059330Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 27 |
| NCT01953731Healthy · United States | 1 | Completed | Pfizer | Jan 2014 | 15 |
| NCT01942135Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Pfizer | Dec 5, 2014 | 521 |
| NCT01918176Healthy · United States | 1 | Completed | Pfizer | Dec 2013 | 26 |
| NCT01906125Healthy · United States | 1 | Completed | Pfizer | Jan 2014 | 73 |
| NCT01821066Healthy · United States | 1 | Completed | Pfizer | Aug 2013 | 25 |
| NCT01802476Healthy · United Kingdom | 1 | Completed | Pfizer | Jun 2013 | 14 |
| NCT01756781Healthy · United States | 1 | Completed | Pfizer | Jul 2013 | 26 |
| NCT01740427Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Pfizer | Feb 26, 2016 | 666 |
| NCT01684215Neoplasms · Japan | 2 | Completed | Pfizer | Mar 4, 2016 | 61 |
| NCT01602887Breast Neoplasms · United States | 1 | Completed | Pfizer | Nov 2012 | 24 |
| NCT00721409Breast Neoplasms · United States, Canada, France and more | 2 | Completed | Pfizer | Nov 29, 2013 | 177 |
| NCT00555906Multiple Myeloma · United States, Czech Republic, Germany | 2 | Completed | Pfizer | Aug 2012 | 53 |
| NCT00420056Lymphoma, Mantle-Cell · United States | 1 | Completed | Pfizer | Mar 2010 | 17 |
| NCT00141297Neoplasms · United States | 1 | Completed | Pfizer | Jul 2008 | 74 |
How it is read
Names in the registry
- “Palbociclib”, 16 entries
- “PD-0332991”, 12 entries
- “palbociclib”, 5 entries
- “Palbociclib 125mg”, 3 entries
- “Palbociclib alone”, 3 entries
Codes read as this program: PD0332991.
Conditions, from the studies’ own filings
- Breast Neoplasms, 13 studies
- Carcinoma, Renal Cell, 1 study
- Sarcoma, Ewing, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.